Copyright © 2020 FibroGenesis. All rights reserved.

Website Design by Blue Heron Support

Welcome to FibroGenesis

FibroGenesis, is a regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts. Currently, FibroGenesis holds 184 U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.


One area of focus is Degenerative Disc Disease.  Chronic Lower Back Pain afflicts an estimated 33 million people annually in the U.S. Over 7 million of those people suffer from Degenerative Disc Disease. Aging baby boomers may double those numbers in the next two decades. At FibroGenesis, we are the clinical stage world leader in patented fibroblast cell therapy to treat Degenerative Disc Disease.


Back pain is strongly associated with degeneration of the intervertebral disc. Disc degeneration, although in many cases asymptomatic, is also associated with sciatica and disc herniation or prolapse. It alters disc height and the mechanics of the rest of the spinal column, adversely affecting the behavior of other spinal structures such as muscles and ligaments. In the long term, it can lead to spinal stenosis, a major cause of pain and disability in the elderly. Degenerated disc incidence is rising with current demographic changes and an increased aged population.

Recent Developments

March 10, 2020

FibroGenesis Files Patent to Treat Coronavirus (COVID-19) Acute Respiratory Distress Syndrome (ARDS)  Read More


February 3, 2020

FibroGenesis to Present at LSX World Congress  Read More


January 28, 2020

SpinalCyte Changes Name To FibroGenesis  Read More


December 12, 2019

SpinalCyte CEO, Pete O'Heeron named to 30 Best CEOs of 2020 List

See List Here

Read Interview Here

Read Press Release Here

December 11, 2019

SpinalCyte Announces New Australian Patent 

Read More


October 23, 2019

CEO/CFO Magazine Interviews SpinalCyte CEO,

Pete O'Heeron  Read More

October 21, 2019

SpinalCyte to Present at BIO Investor Forum  

Read More


October 15, 2019

SpinalCyte Announces New Japanese Patent 

Read More


September 19, 2019

SpinalCyte Announces New International Patent 

Read More


June 5, 2019

SpinalCyte to Present at Boao Forum in Qingdao, China  Read More

May 15, 2019

SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology  Read More

March 28, 2019

SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting  Read More


March 18, 2019

SpinalCyte to Present at China Focus @ Europe Vienna, Austria  Read More


March 11, 2019

SpinalCyte Announces Two New Patents  Read More


February 4, 2019

SpinalCyte to Present at the 2019 BIO CEO & Investor Conference  Read More


January 8, 2019

SpinalCyte Announces New International Patent  

Read More